Immunovant Files Automatic Shelf Registration Statement
Immunovant, Inc. has filed an automatic shelf registration statement (S-3ASR) with the SEC, allowing for the potential future offering of securities.
Stocks · News reference
Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunovant, Inc. has filed an automatic shelf registration statement (S-3ASR) with the SEC, allowing for the potential future offering of securities.
Truist Securities has raised its price target for Immunovant, Inc. from $30.00 to $33.00 while maintaining a 'Hold' rating on the stock.
Immunovant announced its financial results for the second fiscal quarter ended September 30, 2026, reporting a loss of $0.47 per share.